This page shows the latest DMD news and features for those working in and with pharma, biotech and healthcare.
DMD aged four to five years on 22 June this year, rather than the originally proposed 29 May date. ... SRP-9001 is designed to address the underlying cause of DMD through the targeted production of functional components of dystrophin in muscle tissue.
A US Food and Drug Administration’s (FDA) panel of experts has recommended Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) investigational gene therapy for accelerated approval. ... SRP-9001 is designed to address the underlying cause of DMD
AAV-based gene therapy for the treatment of Duchenne muscular dystrophy (DMD), the company’s partner Hansa Biopharma AB (Hansa) announced. ... Sarepta submitted a Biologics License Application to the US Food and Drug Administration in September for the
DMD is a rare inherited X-chromosome-linked disease, almost exclusively affecting males, and is caused by a change or mutation in the gene that encodes instructions for dystrophin, meaning those ... as Promising Innovative Medicine status from the UK
DMD). The announcement follows updated clinical trial results from the company’s ENDEAVOR study in July, which bolstered the data for SRP-9001 for efficacy and durability. ... DMD affects approximately one in every 3, 500-5, 000 newborn males worldwide.
Sarepta Therapeutics has revealed some early promising data for its Duchenne muscular dystrophy (DMD), although the company also reported serious adverse events associated with the treatment. ... Roche. The study, which has so far enrolled 20
More from news
Approximately 9 fully matching, plus 52 partially matching documents found.
Like other DMDs, metal exposure should be avoided,” adds Ben- Amor, who has been involved in MS research and business operations for 20 years.
additional $160m more in near-term milestones if drisapersen, the late-stage drug for Duchenne muscular dystrophy (DMD), secures “early” approval. ... Prosensa has been busy since drisapersen failed a pivotal phase III for DMD (failure to beat a
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
We look forward to leveraging his capabilities as we advance our clinical development pipeline, particularly CAT-1004 for Duchenne muscular dystrophy (DMD), and our lipid programmes, CAT-2003 and CAT-2054.”. ... we seek to bring disease-modifying
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Benjamin is a trustee and patient advocate for DMD Pathfinders and has recently completed a Masters in Scientific Communications.
for instance to treat haemophilia, rare ophthalmic disorders and for Duchenne muscular dystrophy/DMD), genetic therapies are likely to represent a revolution in medicine over the coming years. ... However, in most areas where genetic treatments are being
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
We focus on what matters most…. Driven by insight, expertise and fresh thinking, our award-winning communications programmes are designed to...